TIDES

A specialized class of therapeutics consisting of peptides (chains of amino acids) and oligonucleotides (short DNA or RNA molecules).

TIDES is an industry acronym representing peptides (chains of amino acids) and oligonucleotides (short DNA or RNA molecules). These complex, large-molecule therapeutics represent a specialized class of drug modalities. They are highly valued in drug development because they can target biological pathways and genetic drivers of disease that traditional small-molecule drugs or larger monoclonal antibodies cannot reach. Investors track TIDES pipelines and manufacturing capacity because these therapeutics require highly specialized chemical synthesis, purification, and analytical technologies. Unlike standard small-molecule drugs, which are relatively simple to manufacture, or biologics, which are grown in living cells, TIDES molecules are produced through complex, automated chemical synthesis. This creates high barriers to entry and strong pricing power for companies with advanced capabilities. When evaluating companies in this space, investors look at the depth of the clinical pipeline and the utilization rates of specialized manufacturing facilities. High-capacity, high-efficiency production translates to strong gross margins, while manufacturing bottlenecks or regulatory compliance failures at production facilities represent significant downside risks.

A contract development and manufacturing organization (CDMO) invests $100 million to build a specialized TIDES synthesis suite. If the suite operates at full capacity, generating $150 million in annual revenue with $60 million in operating costs, the operating margin for this high-barrier segment is calculated as: ($150 million - $60 million) / $150 million = 60%.